Abstract

Prostate cancer is the most commonly diagnosed cancer among men worldwide. Androgen deprivation therapy has been a well established treatment for prostate cancer and improves disease-free survival in combination with radiation therapy in patients with locally advanced disease, but has been associated with bone loss and increased fracture risk. Fractures are an important contributor to morbidity associated with androgen deprivation therapy. Existing therapies have shown prevention of bone loss, but have yet to demonstrate reduction in fractures. Denosumab, a human monoclonal antibody that inhibits receptor activator for nuclear factor-κB ligand, impacts osteoclasts formation and survival, and has been shown to increase bone density in postmenopausal osteoporosis and other hormone deprivation states.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.